[116] J
Specifically, we are proposing to replace part 1141 to Title 21 of the Code of Federal Regulations (21 CFR part 1141), and the new part 1141 would require new cigarette health warnings [1] on cigarette packages and in cigarette advertisements
doi:10.1097/chi.0b013e3181b5dbfe
Cardiac disorder: chest pain, dyspnea, palpitations Gastrointestinal disorders: abdominal pain, nausea, vomiting, diarrhea General disorders and administration site conditions: chest pain, fatigue, pain, malaise, injection site pain or erythema, feeling abnormal, pyrexia, condition aggravated, asthenia Immune system disorders: hypersensitivity reactions, including pruritus, rash, urticaria, erythema Injury, poisoning, and procedural complications: injury Investigations: weight decreased Musculoskeletal and connective tissue disorders: pain in extremity, arthralgia, back pain, muscle spasm Nervous system disorders: headache, migraine, dizziness, hypoesthesia, paresthesia Psychiatric disorders: depression, insomnia, anxiety Reproductive system and breast disorders: metrorrhagia, menorrhagia, hot flush, vaginal hemorrhage Respiratory, thoracic, and mediastinal disorders: nasopharyngitis, cough Sleep disorders and disturbances: somnolence Vascular disorders: deep vein thrombosis, pulmonary embolism Consult the labeling of concurrently used drugs to obtain further information about interactions with hormonal contraceptives or the potential for enzyme alterations
Neurotoxicology 89:140160
2016;25(2):ii626
